Both private and public healthcare systems, in the coming years, will accelerate the adoption of products that can simultaneously improve the cost of healthcare delivery and clinical effectiveness. Companion Diagnostic (CDx) products have proven themselves to be considerably more profitable and clinically desirable than a stand-alone diagnostic test or a "blind" prescription.
TTS Pharma Ltd is in the vanguard of personalised medicine by offering the “Right drug to the Right patient at the Right dose”. With over 25years of experience in the Drug Delivery sector the company has acquired, developed and blended several patented and validated technologies to enable the pharmacogenetic stratification of patients and accurate prescriptive treatment via transdermal drug delivery. Together these technologies assist the clinician in selecting the most appropriate course of treatment and introduce material advantages in both unit cost and clinical utility to benefit both the patient and payor.